irritable bowel syndrome – improvement to the clinical situation by the use of humic acid - WH67® - irritable bowel syndrome

WH Pharmawerk Weinböhla GmbH0 个研究点目标入组 46 人开始时间: 2013年8月2日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•irritable bowel syndrome - diarrhea-predominant (RDS-D) --> according to ROM III criteria (diarrhea / pain)
•male and female patients = 18 years
•patients, who are willing and able to realise the study visits (e.g. no planned holidays)
•patients, who are willing and able to complete the patient diary
•last to weeks (screening phase) at least two times complaints (pain, discomfort) per week
•willing to forgo medications of the forbidden medication list
•Written informed consent

•irritable bowel syndrome - obstipation-predominant (RDS-O)
•diagnosed, inflammatory bowel disease, as Morbus Crohn, Colitis ulcerosa, chronic inflammatory bowel disease
•clinical reference to colon cancer (colonoscopy without pathological findings from the last 5 years for patient > 55 years)
•clinical reference to an acute infection
•history of known chronic gastritis or inflammatory bowel diseases
•history of known coeliac
•history of known lactose intolerance
•patients with serious diseases in connection with vital medications
•naturopathic measures regarding irritable bowel syndrome during the last 6 months before screening
•current regular intake of medications influencing motility
•addiction
•history of known hypersensitivity compared to the substances / medical product
•participation in other interventional trials during the last 4 weeks before screening
•knowing pregnancy

发起方

WH Pharmawerk Weinböhla GmbH